. Author manuscript; available in PMC: 2019 Jun 1.

Published in final edited form as: J Thromb Haemost. 2016 Sep 17;14(10):1960–1970. doi: 10.1111/jth.13431

Table 3.

Sensitivity analyses of the association between rs62187992 and tissue factor pathway inhibitor plasma levels in the F5L Family Study and MARTHA Study

	F5L Family Study			MARTHA Study
	N	Effect (SE)	P	N	Effect (SE)	P
Primary analysis	251	0.16 (0.07)	0.020	1033	0.13 (0.04)	6.27 × 10⁻⁴
Covariate adjustment^*	227	0.16 (0.06)	0.015	848	0.06 (0.04)	0.088
Males	125	0.26 (0.09)	0.008	349	0.11 (0.05)	0.038
Females	126	0.08 (0.09)	0.363	684	0.11 (0.05)	0.022
Body mass index < 25 kg m⁻²	108	0.15 (0.09)	0.102	524	0.15 (0.05)	0.006
Body mass index ≥ 25 kg m⁻²	140	0.21 (0.10)	0.046	470	0.08 (0.05)	0.096
No history of venous thromboembolism	234	0.19 (0.07)	0.006	NA	NA	NA
History of venous thromboembolism	15	0.05 (0.26)	0.864	1033	0.13 (0.04)	6.27 × 10⁻⁴
F5L non-carriers	188	0.11 (0.08)	0.169	793	0.11 (0.04)	0.006
F5L carriers	63	0.23 (0.14)	0.103	237	0.07 (0.09)	0.436
No female hormone therapy use	225	0.17 (0.07)	0.017	966	0.11 (0.04)	0.002
No antithrombotic drug use^†	200	0.15 (0.07)	0.046	729	0.12 (0.04)	0.004
Excluding extreme values^‡	248	0.12 (0.06)	0.059	1028	0.11 (0.04)	0.003

F5L, factor V Leiden mutation; NA, not applicable; SE, standard error.

Covariate adjustment included HDL, lipoprotein(a), von Willebrand factor and FVII in the F5L Family Study, and oral contraceptives, F5L, body mass index, von Willebrand factor and protein S in the MARTHA Study. In both study samples, potential covariates were identified from the literature, and associated covariates were identified by backwards model selection.

^†

Antithrombotic medication included vitamin K antagonists and antiplatelet agents.

^‡

Extreme values were defined as greater than three times the interquartile range from the third quartile in the study sample from which the individual originated.